Isofol Medical AB (ISOFOL) - Total Liabilities
Based on the latest financial reports, Isofol Medical AB (ISOFOL) has total liabilities worth Skr21.52 Million SEK (≈ $2.32 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Isofol Medical AB's assets to evaluate the company's liquid asset resilience ratio.
Isofol Medical AB - Total Liabilities Trend (2011–2025)
This chart illustrates how Isofol Medical AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Isofol Medical AB balance sheet assets.
Isofol Medical AB Competitors by Total Liabilities
The table below lists competitors of Isofol Medical AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Caldwell Partners International Inc
TO:CWL
|
Canada | CA$36.43 Million |
|
Studio Mir Co. Ltd.
KQ:408900
|
Korea | ₩3.93 Billion |
|
DAP Corporation
KQ:066900
|
Korea | ₩135.71 Billion |
|
Xbrane Biopharma AB
ST:XBRANE
|
Sweden | Skr103.76 Million |
|
HG Capital Trust PLC
LSE:HGT
|
UK | GBX38.12 Million |
|
Ratio Energies LP
TA:RATI-L
|
Israel | ILA768.11 Million |
|
Investors House
HE:INVEST
|
Finland | €18.01 Million |
|
Alpcot Holding AB Series B
ST:ALPCOT-B
|
Sweden | Skr98.89 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Isofol Medical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ISOFOL net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Isofol Medical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Isofol Medical AB (2011–2025)
The table below shows the annual total liabilities of Isofol Medical AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr21.52 Million ≈ $2.32 Million |
+5.14% |
| 2024-12-31 | Skr20.47 Million ≈ $2.20 Million |
+6.83% |
| 2023-12-31 | Skr19.16 Million ≈ $2.06 Million |
-65.15% |
| 2022-12-31 | Skr54.99 Million ≈ $5.92 Million |
-33.86% |
| 2021-12-31 | Skr83.13 Million ≈ $8.95 Million |
+1.92% |
| 2020-12-31 | Skr81.56 Million ≈ $8.78 Million |
+96.24% |
| 2019-12-31 | Skr41.56 Million ≈ $4.47 Million |
+76.53% |
| 2018-12-31 | Skr23.54 Million ≈ $2.53 Million |
+29.06% |
| 2017-12-31 | Skr18.24 Million ≈ $1.96 Million |
+8.65% |
| 2016-12-31 | Skr16.79 Million ≈ $1.81 Million |
+98.59% |
| 2015-12-31 | Skr8.46 Million ≈ $909.89K |
+240.10% |
| 2011-12-31 | Skr2.49 Million ≈ $267.54K |
-- |
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.